Myocardial infarction (MI) is the leading cause of death worldwide and extensive research has therefore been performed to find a cure. Neuregulin-1 (NRG) is a growth factor involved in cardiac repair after MI. We previously described how biocompatible and biodegradable microparticles, which are able to release NRG in a sustained manner, represent a valuable approach to avoid problems related to the short half-life after systemic administration of proteins. The effectiveness of this strategy could be improved by combining NRG with several cytokines involved in cardiac regeneration.
Introduction:
Cardiovascular diseases cause more than 17 million deaths each year according to the latest report of the World Health Organization (available in http://www.who.int/cardiovascular_diseases), constituting the greatest health risk in western countries [1] . Despite the advances in pharmacological treatment, a major improvement able to repair the massive loss of cardiomyocytes after a myocardial infarction (MI) has not yet been reached, heart transplantation being the only real option for severe cases. Due to this situation new approaches have been explored in the last few years [2] [3] [4] [5] . One of these strategies is the use of growth factors (GF). GF are thought to benefit the damaged heart through direct effects in the myocardium and by stimulating and mobilizing progenitor cells [6] . However, GF protein administration presents serious limitations due to their short in vivo half life, physical and chemical instability, and the low oral bioavailability of these macromolecules [7] . The use of drug delivery systems (DDS) that encapsulate GF might overcome these drawbacks.
Microparticles (MP), one of these DDS, could protect proteins from degradation and ensure sustained release among time [8] . Recently, our group explored new therapeutic strategies for MI treatment, based on the use of polymeric MP that release different GF involved in cardiac angiogenesis and neovascularization [8] [9] [10] [11] . Neuregulin-1 (NRG) deserves special attention in heart regeneration because it is involved in cardiac repair after MI [12] . This protein plays a crucial role in the adult cardiovascular system by inducing sarcomere membrane organization and integrity [13] , cell survival [14, 15] and angiogenesis [16] . We recently proved that NRG-releasing MP promoted cardiac repair and improved cardiac performance [11] . NRG-releasing MP effectiveness could be improved by combining this protein with several other cytokines involved in cardiac regeneration. This could be achieved by preparing a polymer-based GF delivery system that allows the release of multiple factors [6] . However, to date GF delivery systems have not demonstrated the ability to deliver cocktail of factors with distinct kinetics [17] . This aspect, besides the limitation that GF dose and timing are crucial for helping regeneration, makes it difficult to co-administer different GFs [6, 7] . The combination of NRG-releasing MP with cytokines secreted by stem cells (SC), capable of responding to the host environment, opens up a possible solution to that drawback. Moreover, MP possess many features that make them suitable for use as cardiac scaffolds. In particular, they are biodegradable, biocompatible, non-toxic and, importantly, they can provide structural support for cell survival and differentiation [18] [19] [20] [21] [22] [23] [24] .
Among the different SC sources, adipose-derived stem cells (ADSC) have shown promising results in cardiac repair [25] [26] [27] [28] . They are good candidates for cell therapy studies because of their easy isolation from the stromal vascular fraction [29] [30] [31] [32] and their extensive differentiation potential. In addition, ADSCs are able to secrete angiogenic and/or anti-apoptotic factors [33] , such as granulocyte-macrophage colony stimulating factor (GM-CSF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor (bFGF), and transforming growth factor-β (TGF-β) [31] .
For all of these reasons, the primary purpose of this work was to investigate the potential feasibility of NRG-releasing particle scaffold combined with ADSC as a multi GF delivery-based tissue engineering strategy for the ischemic heart. To this end, NRGreleasing delivery system was prepared using Total Recirculation One-Machine System (TROMS), a technique based on the multiple emulsion solvent evaporation method which is suitable for the encapsulation of labile molecules like cytokines and GFs [8, 34] . We primarily investigated the physical characteristics of the particle scaffold such as morphology or size. Then, NRG-releasing particle scaffolds were combined with ADSC and flow properties such as dispersability and injectability of the ADSC particle scaffold suspension were analyzed to avoid complications during their administration.
The myocardial response to ADSC combined with NRG-releasing particle scaffold was finally evaluated using a MI rat model to ensure safety and biocompatibility requirements.
Materials
Poly(lactic-co-glycolic acid) (PLGA) with monomer ratio (lactic acid/glycolic acid) of 50:50 Resomer® RG 503H (Mw: 34 and horseradish-peroxidase-conjugated donkey anti-goat IgG (sc-2020) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Preparation of NRG-releasing particle scaffold
NRG-releasing PLGA particle scaffolds were prepared by the emulsion solvent evaporation method using TROMS as previously described [11] with minor modifications. In order to obtain batches with the defined particle size the following TROMS parameters were adjusted: pumping flow, recirculation times to obtain both Particle scaffolds were washed three times with ultrapure water by consecutive centrifugations at 4 °C (20,000×g, 10 min). NRG-releasing particle scaffolds were lyophilized for 48h without cryoprotective agents (Virtis Genesis 12 EL, Gardines, NY). The conditions of freeze drying were -50ºC to +15ºC over 2 days. After complete lyophilization, the vials were sealed under vacuum and stored at -20°C until use.
Unloaded particle scaffolds were prepared in the same manner without adding NRG.
For fluorescence-labeled formulation, rhodamine B isothiocyanate (0.5 mg/mL) was added to the inner aqueous phase and particle scaffolds were prepared as described.
NRG-releasing PLGA particle scaffold characterization

Particle size analysis
The mean particle size and size distribution were examined by laser diffractometry using a Mastersizer® (Malvern Instruments, Malvern, UK). Particle scaffolds were dispersed in ultrapure water and analyzed under continuous stirring. The average particle size was expressed as the volume mean diameter in micrometers.
Drug content
The amount of NRG encapsulated in the particle scaffold was determined by dissolving 0.5 mg of lyophilized loaded particles in 25 µL of DMSO, and was quantified using western blot. After electrophoresis and transference, the membranes were blocked with 5% nonfat dried milk in TBS plus 0.05% Tween 20 for 2 h, then Sample values were quantified using a blotting standard curve with known amounts of NRG.
In vitro bioactivity assay
The bioactivity of NRG released from particle scaffolds was evaluated in vitro by determining the proliferative capacity of H9c2 cells after NRG treatment. H9c2 cells obtained from embryonic BD1X rat heart tissue were cultured in DMEM medium supplemented with 10% FBS, 1% glutamine and 1% penicillin/streptomycin at 37 °C under 5% CO 2 /95% air [35] [36] [37] . Cells were subcultured when 60% confluency was achieved. In order to quantify cell proliferation after NRG stimulation, cells were seeded in 96-well tissue culture plates at a density of 2 × 10 3 cells/well. After 24 h, medium was removed and the cells were incubated with 150 ng/mL of NRG released from particle scaffolds over 24 h, which had previously been quantified by western blot, with 150 ng/mL of free NRG or medium alone as control. that expressed the green fluorescent protein (GFP), as previously described [38] . ADSC cells were cultured in α-MEM medium supplemented with 10% FBS, 1 ng/mL bFGF and 1% penicillin/streptomycin. Cells were subcultured when 80% confluence was reached.
Adhesion of ADSC cells to particle scaffold
To favor cell attachment to the MP surface, the particle scaffold was overlaid with 0.5 μg/cm 2 of type 1 collagen and/or PDL [18] . Particle scaffold coating was performed in 15 mL falcon tubes. Scaffolds were re-suspended in DPBS and the mixture was 
In vivo studies using chronic myocardial infarction model
All animal procedures were approved by the University of Navarra Institutional [11] . Briefly, rats were anesthetized with 4% isoflurane in an induction chamber and supported with a mechanical ventilator. Prior to surgery, animals received analgesic drug ketoprofen 5 mg/Kg subcutaneously. The rats were then intubated and 1.5-2% isoflurane was maintained for continuous anesthesia. The heart was accessed through a left thoracotomy through the fourth intercostal space, and the left anterior descending coronary artery was permanently occluded 2-3 mm distal from its origin.
The chest was then closed in layers and rats allowed to recover on a heating pad.
Intramyocardial implantation
Seven days post-myocardial infarction, rats were placed into the following and 3 were injected with rhodamine B fluorescent particle scaffolds to visualize particles by fluorescent microscopy. All the treatments were injected in 4 sites of the border zone surrounding the infarct zone using a 23 G needle. After treatment injection, the chest was closed and rats were allowed to recover on a heating pad.
Histological assessment of myocardial tissue after treatment implantation
Two weeks after treatment implantation, animals were sacrificed and hearts were collected for histology. After being harvested, the hearts were perfused-fixed in 4%
paraformaldehyde at 4 °C, and sliced in three 4-mm-thick segments from apex to base.
The hearts were dehydrated in ethanol 70% at 4 °C, embedded in paraffin and 5-μm-sections were cut. Hematoxylin-eosin (HE) staining was performed to visualize tissue structure and to study tissue retention of implanted treatment.
Verification of NRG-releasing particle scaffold retention in the infarcted tissue and ADSC cell fate
Fluorescence microscopy was used to evaluate tissue retention of rhodamine particle scaffold and the fate of the ADSCs cells.
Results and Discussion
Characterization of NRG-releasing particle scaffold prepared by TROMS
3.1.1 Particle size NRG-releasing particle scaffolds were successfully prepared by W 1 /O/W 2 emulsion/extraction method using TROMS technology. The mean particle size measured by laser diffractometry was distributed around a mean size of 20 ± 5 µm, with a range of 2 to 70 μm. As can be seen in Fig. 1A , particle scaffolds size distribution confirms that TROMS allows the obtention of reproducible batches of MP of a desired particle size.
MP with a size of 20 µm were selected as scaffolds for ADSCs. The particle size was chosen on the basis of previous research by our group in cardiac regeneration [8, 9, 11] , where particles with different size were prepared and characterized to select the most suitable size for intramyocardial administration of GF [9] . In the present paper a slight modification in the particle size was made considering a balance between having sufficient surface for cell adhesion and not causing damage to the heart. The best device settings to obtain 20 µm particles were: 20 mL/min as pumping flow, 90 s and 60 s as [11] . Modifications in the preparation process resulted in 25% higher encapsulation efficiencies than those prepared before. The high NRG entrapment achieved could be related to the encapsulation method and to the use of TROMS to prepare the multiple emulsion system. On the one hand, the water/oil/water evaporation technique has been described as resulting in extremely efficient loading of biodegradable microparticles with hydrophilic compounds [39, 40] and, on the other hand, higher encapsulation efficiencies were found using TROMS compared to conventional encapsulation techniques. For instance, for VEGF, an encapsulation efficiency of 83.8 % was achieved using TROMS [8] . In contrast, King et al. reported an entrapment efficiency of 16 % using the solid/single emulsion/ solvent extraction technique to prepare the microparticles [41] .
NRG is a GF involved in cardiac repair after MI that deserves special attention in heart regeneration [12] . Multiple in vivo studies have established the therapeutic potential of this cytokine after MI. NRG administration after myocardial injury improved systolic function, reduced infarct size and attenuated myocardial hypertrophy in small and large animal models of MI [12] . Its beneficial effects might be due to myocyte protection from death stimuli and through repair of dysfunctional cardiac myocytes [12] . Several clinical trials to evaluate the effect of NRG in humans are ongoing. However, cytokine therapy efficacy is generally hindered for the short plasma half live, gastrointestinal tract instability and low bioavailability of proteins. Thus, the development of a DDS able to release NRG in a sustained manner would improve its potential and efficacy.
In vitro bioactivity assay
The bioactivity of encapsulated NRG released from the particle scaffolds was evaluated in vitro by determining its capacity to induce H9c2 proliferation (Fig. 1B) .
The daily addition of NRG released from particle scaffolds (150 ng/mL) induced a statistically significant 1.24 fold increase in the proliferation of H9c2 in comparison with control (culture medium without cytokine) after 3-day treatment. The increase was similar to that observed when H9c2 cells were cultured with the daily addition of free NRG for 3 days at doses of 150 ng/mL indicating that the biological activity of NRG was maintained after encapsulation and release from particle scaffolds prepared by TROMS.
Adhesion of ADSC to NRG-releasing particle scaffold
The development of a DDS able to protect NRG from degradation and to ensure its sustained release throughout time would reinforce NRG efficacy in cardiac repair as it was mentioned before in this section. Moreover, in the present work we move one step forward combining NRG DDS with ADSC able to secrete multiple cytokines involved in cardiac regeneration. Interestingly, this is the first report of NRG-releasing scaffold for cardiac tissue engineering applications. The importance of multiple growth factor action in cardiac tissue regeneration has been extensively described [19, 21, 42] .
In this regard, the possibility of increasing the beneficial effect obtained with NRG releasing particles combining this DDS with several other cytokines secreted by SC would open up new possibilities in heart regeneration. Among SC, ADSC are particularly suitable for cell therapy because of their easy isolation from the stromal vascular fraction [29] [30] [31] [32] , their extensive differentiation potential and the secretion of several angiogenic and anti-apoptotic factors that activate the revascularization process and the positive remodeling of the heart [31, 33] . Although it is known that ADSC exert their positive effect via paracrine secretion, the beneficial factors remain partly unidentified. Moreover, it is possible that multiple factors might be functioning synergistically [43] [44] [45] . For that reason, ADSC transplantation for their paracrine effects still represents a reasonable strategy. In addition, SC are able to sense and respond to changes in the host environment modifying its paracrine secretion. Moreover, until now, NRG secretion by ADSC has not been described, meaning that the association of these two strategies might have complementary effects on cardiac tissue repair.
In the present study, the adhesion of 2,5 X 10 5 or 5 X 10 5 ADSC to particle scaffolds coated with different concentrations of collagen and PDL was studied. The concentration that showed better adherence was 0.5 μg/cm 2 , either with the collagen or the mixture of collagen and PDL (1:1). The administration of these amounts of cells induced an improvement in the cardiac function when administered in combination with collagen-based carrier sheets after MI [26] . On the other hand, the dose of NRG administered with that quantity of MP also promoted cardiac repair and improved cardiac performance.
Both cell densities adhered efficiently to all particle scaffolds assayed. Observations of cell adhesion over time indicated that collagen coated particle scaffolds required 4 h for total cell attachment while particle scaffolds coated with collagen and PDL attached to the cells after 2 h (Fig. 2) . Differences in cell adhesion time might be due to collagen and PDL net charge at pH value of the culture medium used for adhesion (pH 7.2).
Thus, collagen net charge at pH 7.2 is negative due to its isoelectric point of 5.5, hindering cell adhesion. On the other hand, PDL with an isoelectric point of 12.9, has a net charge positive at pH 7.2 that favors the adhesion of the cells. As in the coating and adherence processes a certain amount of encapsulated NRG is released over time, the less time required for ADSC NRG-particle scaffold preparation, the less amount of NRG would be lost during the manufacture process.
The use of biodegradable microparticles as injectable scaffolds for tissue engineering applications was first proposed by Montero-Menei C. N. and colleagues [46, 47] . After that, several authors investigated their potential to improve cell survival and differentiation [18-20, 22-24, 48] . The differentiation of ADSC towards a cardiac lineage is, however, not the main objective of the present research. ADSC cells were combined with NRG delivery systems for their beneficial paracrine effect on endogenous cells. Thus, a multidrug delivery system able to respond to the surrounding tissue would be obtained.
Dispersability and injectability of NRG-releasing particle scaffold combined with ADSC
The injection of ADSC-particle scaffolds in the infarcted heart required the selection of a good dispersing medium that allows the cell-particle scaffold suspension to pass through a needle without needle blockage or sedimentation. A cell-particle scaffold suspension with good rheological properties will ensure dose uniformity and safety requirements during the local myocardial injection of the treatments. Two dispersing media containing different percentages of DMEM, carboxymethyl-cellulose, polysorbate 80 and mannitol were investigated in the present study. These excipients are included in the Handbook of Pharmaceutical Excipients [49] and are frequently used in commercial formulations. DMEM is a solution commonly used for drug/cell injection into the infarcted heart [50, 51] , carboxymethyl-cellulose is a wetting and biocompatible agent that prevent particle aggregation and makes their injection through a thin needle and polysorbate 80 and mannitol has been previously used to suspend PLGA microparticles prior to intracerebral implantation [34] . The ADSC particle scaffold suspension showed the best flow properties in the dispersing medium containing 0.4% (w/v) carboxymethyl-cellulose, 3.2% (w/v) polysorbate 80 and 3.2%
(w/v) mannitol in PBS, pH 7.4. No toxicity or cell detachment was observed when using this medium.
Prior to injection in the infarcted myocardium, the injectability of the cell-particle scaffold suspension was analyzed. To this end, ADSCs adhered to 20 µm particle scaffolds were delivered through needles with different diameter (23, 24, 25, 27 and 29 G) . ADSC particle scaffolds were only able to go through the 23G needle without blocking or sedimentation, and carrying ADSC cells adhered on the surface. This needle was therefore used for intramyocardial administration (Fig. 3 ).
Histological evaluation of myocardial tissue after the injection of NRGreleasing particle scaffold combined with ADSC
Finally, ADSC combined with empty or cytokine delivery systems coated with collagen or collagen:PDL were intramyocardially injected in the infarcted beating heart (Fig. 3) . Two weeks later, animals were sacrificed to further evaluate myocardial tissue reaction and the non-toxic properties of the implanted scaffold in vivo. Upon implantation, hematoxylin and eosin staining revealed that ADSC particle scaffolds were well tolerated by the infarcted myocardium and they seem to integrate well within the host tissue (Fig. 4 C,D) . Heart response after ADSC-scaffold injection was the typical reaction observed following mechanical trauma and exposure to a foreign body.
ADSC-scaffolds (Fig. 4 C,D) did not induce inflammatory reactions when compared to resuspension medium injection (Fig. 4 A,B) . Hematoxilin and eosin staining did not evidence noticeable differences in terms of biocompatibility and local tolerance between groups. Moreover, the tissue adjacent to the implanted treatments maintained its physiological characteristics and no adverse cellular reactions were observed.
Confirmation of NRG-releasing particle scaffold retention in the infarcted heart and ADSC cell fate
Fluorescent and brightfield microscopy showed that two weeks after intramyocardial implantation, particle scaffolds appeared grouped at the implantation site independently of the coating used to attach ADSC (Fig. 4 C,D and 5 A,B) . At day 14, particle scaffolds were not totally biodegraded and a significant quantity of them were still detectable. No differences in terms of scaffold degradation were observed among the various groups during the two-week implantation period. As can be seen in Taking together our in vitro ADSC adhesion studies and our present in vivo biocompatibility findings on infarcted rats, 5 X 10 5 ADSC cells combined with NRGreleasing particle scaffolds coated with collagen and PDL will be selected to further assess the therapeutic potential of this strategy in cardiac regeneration.
Conclusion
The data presented is this article offers valuable evidence of the feasibility of using NRG-releasing particle scaffolds combined with ADSC as a multi GF deliverybased tissue engineering strategy to treat the ischemic heart. Future studies will be focused on the response produced by the treatment, to demonstrate whether the combination of ADSC with NRG and using particle scaffolds as support is helpful in the regeneration of the infarcted heart. Nrg-releasing particle scaffold implantation. Seven days after LAD coronary artery occlusion, ADSC combined with Nrg-releasing particle scaffolds were injected into the peri-infarct zone through a 1-mL insulin syringe with a 23-G needle while the heart was beating. Note the presence of the ADSC-scaffold in the beating heart demonstrating that ADSC-scaffolds were not washed out from the infarcted myocardium. 
